ASLAN003 is an orally active, potent inhibitor of DHODH that has the potential to be first-in-class in AML. Licensed from Almirall in 2012, we have global rights for all non-topical and non-dermatological indications. AML is a cancer of the myeloid line of blood cells, characterised primarily by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. We are conducting a Phase 2 clinical trial to develop ASLAN003 in AML, with part 1 of the phase 2 data expected in 1H 2019. We are also exploring other solid tumour types where DHODH may be relevant, such as TNBC and HCC.
ASLAN003 has the potential to be a first-in-class DHODH inhibitor in oncology due to the following competitive advantages:
ASLAN has partnered with Almirall for the development of ASLAN003. Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. The company, founded in 1943 and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM).
To learn more about Almirall, please visit www.almirall.com
ASLAN has partnered with BioGenetics for the commercialisation of varlitinib and ASLAN003 in South Korea. BioGenetics, formerly Unidus Corporation, is a Korea-based company established in 1973 engaged in the manufacturing of medical products. As part of the company’s diversification strategy, BioGenetics established its biopharmaceutical division in April 2018 and appointed Mr Joohoon Ahn, as CEO of the newly established division. Mr Ahn was most recently Senior Managing Director at Kwangdong Pharmaceuticals, one of the top 3 domestic pharmaceutical companies in Korea, and has 28 years of experience in the Korean pharma industry in regulatory affairs, commercialisation, and business development. Biogenetics is co-developing WM-S1-001 for Erbitux®-resistant colon cancer with WellMarkerBio, a spin-off company from Asan Medical Center, one of the largest private hospitals in Korea.